Clinical bottom line
Low-dose naltrexone (LDN) is an emerging, putative therapeutic option for symptom management in patients with postural orthostatic tachycardia syndrome (POTS), a complex form of orthostatic intolerance characterized by excessive heart rate increase upon standing. Current evidence supporting LDN use in POTS is limited to small case series and anecdotal reports, with no randomized controlled trials to date. While preliminary observations suggest potential benefits in symptom relief and quality of life, the evidence remains hypothesis-generating and warrants rigorous validation before routine clinical adoption in primary care.
What the evidence shows
POTS is a heterogeneous syndrome involving autonomic dysregulation, often presenting with palpitations, dizziness, fatigue, and cognitive impairment, complicating diagnosis and management in primary care (Hulsey et al., 2023; Fedorowski et al., 2018). Conventional management includes non-pharmacological strategies and off-label pharmacotherapies targeting heart rate and volume status, but many patients remain symptomatic (Low et al., 2014).
A recent case series by Stallkamp Tidd et al. (2023) explored the use of LDN, an opioid receptor antagonist at low doses, hypothesized to modulate neuroinflammation and autonomic function, in a small cohort of POTS patients. The authors reported subjective improvements in fatigue, pain, and orthostatic symptoms in some patients, with a favorable safety profile. This study represents one of the first clinical reports suggesting LDN’s potential utility in POTS management.
The pathophysiology of POTS involves complex autonomic and inflammatory mechanisms, which may rationalize LDN’s putative benefit given its immunomodulatory effects observed in other chronic conditions (Fedorowski et al., 2018; Low et al., 2003). However, the evidence remains preliminary, and the case series design limits causal inference.
Caveats and uncertainty
The current evidence base for LDN in POTS is extremely limited. The case series by Stallkamp Tidd et al. (2023) included a small number of patients without a control group, standardized outcome measures, or long-term follow-up. Placebo effects and natural symptom variability cannot be excluded. No randomized controlled trials or larger observational studies have yet evaluated efficacy, optimal dosing, or safety in this population.
POTS itself is a heterogeneous syndrome with multiple subtypes and comorbidities, including psychiatric disorders such as anxiety and depression, which may confound symptom assessment and treatment response (Yahya et al., 2020). The mechanisms by which LDN might exert benefit in POTS remain speculative and require mechanistic studies.
Given the absence of guideline endorsement or robust clinical trial data, LDN use in POTS should be considered experimental. Clinicians should weigh potential benefits against unknown risks and engage in shared decision-making with patients.
How this may change practice
For primary care clinicians managing patients with POTS, awareness of LDN as a putative, off-label therapeutic option may be relevant, especially in refractory cases where conventional treatments fail or are poorly tolerated. However, given the paucity of high-quality evidence, LDN should not replace established management strategies.
Clinicians should prioritize comprehensive assessment and multidisciplinary care, including non-pharmacological interventions and symptom-targeted therapies with better evidence. Referral to specialists with expertise in autonomic disorders may be appropriate for complex cases.
If LDN is considered, it should be prescribed cautiously with clear communication about the experimental nature of treatment, close monitoring for efficacy and adverse effects, and documentation of patient consent. Participation in clinical trials, where available, is encouraged to build the evidence base.